Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound ...

Fresenius Kabi voluntarily recalled one lot of morphine sulfate injection due to a labeling mix-up with prefilled syringes of the opioid dilaudid that could trigger an overdose resulting in severe ...

Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with ...

Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.  | In a remarkable turnaround, ...

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...

Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.  | Despite a major curveball thrown by the ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...

News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...

Personalized AI health app VerilyMe is visualizing expanded eye health education in a new partnership with eye health-focused drugmaker Bausch + Lomb.  | The partnership marks Basuch + Lomb's foray ...